| Report Date | |
| Manager | |
| Fund Name | |
| Strategy | |
| Latest Return Date | |
| Latest Return | |
| Latest 6 Months | |
| Latest 12 Months | |
| Latest 24 Months (pa) | |
| Annualised Since Inception | |
| Inception Date | |
| FUM (millions) | |
| Fund Overview | The Fund's discretionary investment strategy commences with a macro view of the economy and direction to establish the portfolio's desired market exposure. Following this detailed sector and company research is gathered from knowledge of the individual stocks in the Fund's universe, with widespread use of broker research. Company visits, presentations and discussions with management at CEO and CFO level are used wherever possible to assess management quality across a range of criteria. Detailed analysis of company valuations using financial statements and forecasts, particularly focusing on free cash flow, is conducted. Technical analysis is used to validate the Manager's fundamental research and valuations and to manage market timing. A significant portion of the Fund's overall performance can be attributed to the attention and importance given to the macro economic outlook and the ability and willingness to adjust the Fund's market risk. |
| Manager Comments | July's return was driven by gold, industrials and key healthcare stocks. Top contributors included A2 Milk, Evolution, Northern Star, Magellan Financial Group, CSL and Polynovo. Detractors included Next Science, Nearmap, Rio Tinto and Audinate Group. The largest detractors were a short position in Share Price Index Futures and the individual short book. Net equity market exposure was increased from 24.9% to 40.5% (73.3% long and 32.8% short), with the key changes being a new long position in Westpac and increased weightings in Commonwealth Bank, James Hardie, Xero, A2 Milk and Macquarie Group. This was partly offset by the sale of NAB and Next Science and four new individual stock shorts in the financials and resources sectors. |
| More Information |